RESEARCH TRIANGLE PARK, N.C. - June 30, 1998 - Quintiles Transnational Corp. (Nasdaq: QTRN) announced today the signing of an agreement with Emory University to collaborate on clinical research opportunities. The non-exclusive agreement also calls for Emory to participate in Quintiles' Select Sites(TM) program.

The agreement is part of Quintiles' Select Sites strategy to develop strong alliances with outstanding academic medical centers, independent investigator sites, and site management and managed care organizations worldwide. The goal is to improve and accelerate the clinical trial process through cooperation in such areas as patient recruitment, protocol design and the use of advanced data collection technologies.

"Providing our customers access to high-performing investigator networks is a vital component of Quintiles' TotalAcceleration(TM) program to improve clinical trials while compressing drug development timelines," said James Hamill, Group Vice President of Quintiles Accelerated Clinical Research. "We're pleased to include Emory University in our efforts to forge strong relationships with outstanding investigator sites worldwide."

Atlanta-based Emory University includes the Robert W. Woodruff Health Sciences Center, the largest and most diversified health sciences research institution in the region, whose physicians are responsible for 2,783 owned or affiliated hospital beds and about 2 million patient visits per year.

"Our network of high-quality academic clinical investigators fits well with Quintiles' worldwide leadership and expertise in clinical trial management and advanced data collection technology," said Victor Lampasona, PharmD, head of Emory's well-established Clinical Pharmaceutical Research Program, which functions as the interface between Emory and Quintiles.

David A. Blake, Ph.D., Associate Director of Emory's Robert W. Woodruff Health Sciences Center and Vice President for Academic Health Affairs, also expressed pleasure with the agreement.

"Emory is increasingly committed to providing the newest medical technologies to patients of Emory Healthcare and Georgians and others throughout the Southeast," Dr. Blake said. "We believe this collaboration with Quintiles as one of the Select Sites will increase our ability to provide our patients opportunities to participate in quality clinical trials of medications that may be important to their health care."

Quintiles Transnational Corp. is the market leader in providing full-service contract research, sales and marketing, healthcare policy consulting and health information management services to the worldwide pharmaceutical, biotechnology, medical device and healthcare industries. Quintiles is headquartered near Research Triangle Park, North Carolina. With 13,000 employees worldwide and offices in 28 countries, Quintiles operates through specialized work groups dedicated to meeting individual customer needs.

Information in this press release contains "forward-looking statements." These statements involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the level of collaboration resulting from the agreement and actual operating performance. Additional factors that could cause actual results to differ materially are discussed in the company's recent filings with the Securities and Exchange Commission, including but not limited to its S-3 and S-4 Registration Statements, its Form 8Ks, its Annual Report on Form 10-K and its periodic reports on Form 10-Q, exhibit 99.01.